Biktarvy
From Proteopedia
(Difference between revisions)
| Line 9: | Line 9: | ||
*<scene name='95/959998/Cv/2'>Emtricitabine</scene>. | *<scene name='95/959998/Cv/2'>Emtricitabine</scene>. | ||
*<scene name='95/959998/Cv/4'>Emtricitabine binding site</scene> at reverse transcriptase ([[2no6]]). Water molecules are shown as red spheres. | *<scene name='95/959998/Cv/4'>Emtricitabine binding site</scene> at reverse transcriptase ([[2no6]]). Water molecules are shown as red spheres. | ||
| + | |||
| + | Tenofovir alafenamide: | ||
| + | *<scene name='98/989318/Cv/1'>Tenofovir alafenamide</scene>. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:58, 29 August 2023
| |||||||||||
References
- ↑ "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet". DailyMed. 8 August 2019. Retrieved 7 March 2020.
- ↑ "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets". U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.
- ↑ "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection" (Press release). Gilead. 7 February 2018.
- ↑ "Biktarvy EPAR". European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.
